Biosimilar Medicines Conference 2018 16th Biosimilar Medicines Conference – Biosimilar medicines: unlocking the full potential of biologics

Biosimilar Medicines Conference 2018 will be a one day Conference and it is going to be on 26 Apr 2018.

The calls you to London, for 16th Biosimilar Medicines Conference – Biosimilar medicines: unlocking the full potential of biologics. It will be settled at Grange Tower Bridge Hotel.

During the meetings of Biosimilar Medicines Conference 2018, you can get the latest updates and detailed information about Biosimilar Medicines, Biology, Biosimilars and Medicine aspects.

Biosimilar Medicines Conference 2018 is an annual Conference.

With 300 expected guests, Biosimilar Medicines Conference 2018 is a prominent event in Pharmaceutical and Biotechnology.

The organizer of the Biosimilar Medicines Conference 2018, 16th Biosimilar Medicines Conference – Biosimilar medicines: unlocking the full potential of biologics is Medicines for Europe.

When you are in London for Biosimilar Medicines Conference 2018, uncover these three must visit parts and adore the enchantment of this city:

• Must do in London
• Must visit in London
• Must taste in London

On 26 & 27 April 2018, London will host the 16th Biosimilar Medicines conference. This year’s flagship event will gather top EU and global regulators, officials, healthcare actors as well as industry leaders, to foster open exchange and debate on the role of the biosimilar medicines sector in “Biosimilar Medicines: Unlocking the Full Potential of Biologics”. Over two days, participants will dive into a dynamic programme – a crossroads between technical, scientific, market discussions and the overarching healthcare policy agenda. With 15 years of experience-sharing on scientific assessment, regulatory approval and the introduction of biosimilar medicines in clinical practice, this conference will take us to new uncharted waters in preparing for this new era. Biosimilar medicines have been game changers in the therapeutic areas where they have been used (e.g. rheumatology, gastroenterology) with positive benefits on access to treatment, and therefore on patient outcomes. They are about to enter cancer patient pathways where the anticipated benefits will represent a unique opportunity for re-investment in needed healthcare products and services.